Absolute lymphocyte count is a prognostic marker in Covid-19: A retrospective cohort review.
Acute Kidney Injury
/ blood
Adult
Aged
Anemia
/ etiology
COVID-19
Coronavirus Infections
/ blood
Female
Hospitals, Teaching
/ statistics & numerical data
Humans
Intensive Care Units
Intubation, Intratracheal
/ statistics & numerical data
Lymphocyte Count
Lymphopenia
/ etiology
Male
Middle Aged
Odds Ratio
Pandemics
Pneumonia, Viral
/ blood
Prognosis
Retrospective Studies
Texas
/ epidemiology
Vasoconstrictor Agents
/ therapeutic use
SARS-CoV-2 infection
acute kidney injury
covid-19
lymphopenia
prognosis
Journal
International journal of laboratory hematology
ISSN: 1751-553X
Titre abrégé: Int J Lab Hematol
Pays: England
ID NLM: 101300213
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
12
05
2020
revised:
26
05
2020
accepted:
21
06
2020
pubmed:
12
8
2020
medline:
28
11
2020
entrez:
12
8
2020
Statut:
ppublish
Résumé
Prognostic factors are needed to aid clinicians in managing Covid-19, a respiratory illness. Lymphocytopenia has emerged as a simply obtained laboratory value that may correlate with prognosis. In this article, we perform a retrospective cohort review study on patients admitted to one academic hospital for Covid-19 illness. We analyzed basic demographic, clinical, and laboratory data to understand the relationship between lymphocytopenia at the time of hospital admission and clinical outcomes. We discovered that lymphocyte count is lower (P = .01) and lymphocytopenia more frequent by an odds ratio of 3.40 (95% CI: 1.06-10.96; P = .04) in patients admitted to the Intensive Care Unit (ICU), a marker of disease severity, relative to those who were not. We additionally find that patients with lymphocytopenia were more likely to develop an acute kidney injury (AKI), a marker of organ failure, during admission by an odds ratio of 4.29 (95% CI: 1.35-13.57; P = .01). This evidence supports the hypothesis that lymphocytopenia can be an early, useful, and easily obtained, prognostic factor in determining the clinical course and disease severity of a patient admitted to the hospital for Covid-19.
Identifiants
pubmed: 32779838
doi: 10.1111/ijlh.13288
pmc: PMC7405282
doi:
Substances chimiques
Vasoconstrictor Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
761-765Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Int J Infect Dis. 2020 Jul;96:131-135
pubmed: 32376308
Int J Lab Hematol. 2020 Dec;42(6):761-765
pubmed: 32779838
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Shock. 2014 Nov;42(5):383-91
pubmed: 25051284
Clin Infect Dis. 2020 Jul 28;71(15):769-777
pubmed: 32176772
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452